Summary
Prometheus has announced a significant funding round, raising $12 billion to further its initiatives in artificial engineering within the biotechnology field.
This investment is part of a broader trend in the biotech industry, which includes the recent acquisition of a cancer drug by the nonprofit Blood Cancer United.
Additionally, companies like Lilly and Nvidia have made investments in Abridge, highlighting ongoing financial activity and interest in biotech advancements.
Key Facts
| Fact | Value |
|---|---|
| Funding Amount | $12 billion |
| Focus Area | Artificial Engineering in Biotech |
Updates
Update at 14:09 UTC on 2026-06-12
STAT reported Nonprofit Blood Cancer United acquires cancer drug, Lilly and Nvidia invest in Abridge, and more biotech news.
Sources: STAT